Latest news
Gilead Sciences announced its financial results for the second quarter of 2026 on August 4, 2026. Total revenue increased by 10% year-over-year to $7.8 billion, mainly driven by a 10% increase in product sales excluding Veklury, reaching $7.6 billion. HIV pr - BitgetBitget · Tue, 04 Aug 2026 21:47:27 GMT[AIDS 2026] Infectious Disease Special Edition: Long-acting Cabenuva shows comparable real-world effectiveness to daily Biktarvy - eatg.orgeatg.org · Sun, 02 Aug 2026 00:12:56 GMTViiV's two-drug Dovato matches three-drug Biktarvy in first head-to-head HIV trial - allsci.comallsci.com · Tue, 28 Jul 2026 08:24:47 GMT[AIDS 2026] [Press release] ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV - eatg.orgeatg.org · Tue, 28 Jul 2026 00:42:10 GMTDovato Shows Noninferior Efficacy to Biktarvy in Head-to-Head HIV Trial - Contagion LiveContagion Live · Mon, 27 Jul 2026 21:05:34 GMTHead-to-head study shows Dovato as effective as Biktarvy in HIV | AIDS 2026 - Managed Healthcare ExecutiveManaged Healthcare Executive · Mon, 27 Jul 2026 07:00:00 GMTViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV - Business WireBusiness Wire · Mon, 27 Jul 2026 07:00:00 GMT